REVBIO, INC. — SEC Form D Filing

REVBIO, INC. filed an SEC Form D on October 2, 2026, reporting $14.99M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 2, 2026
Amount reported
$14.99M
Round stage
Series B+
Industry
Biotechnology
Website
https://revbio.com/

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

There is a long-standing unmet medical need for a regenerative bone glue that effectively repairs and regenerates bone.

Solution

RevBio is developing TETRANITE®, a synthetic bone adhesive biomaterial inspired by the sandcastle worm, designed for wet-field performance, multi-surface bonding, rapid mechanical stability, and controlled biodegradability to transform bone repair.

Why now

Advances in biomaterials science and bioengineering, coupled with a growing demand for less invasive and more effective regenerative solutions in orthopedics, dentistry, and neurosurgery, make this a timely innovation. The market's fragmentation and lack of a universal bone adhesive provide a significant opportunity for a novel, synthetic solution.

Verdict

Investors funded this round due to the compelling, highly legible biomaterials science and the promise of a novel, broadly applicable bone adhesive, not solely for its immediate commercial traction in a specific indication. They implicitly bet on the platform potential of TETRANITE® to disrupt multiple surgical domains, anticipating that the science would ultimately clear the regulatory and market adoption hurdles. The upside was limited by the inherent long development cycles and capital intensity typical of novel medical device platforms, requiring sustained future funding rounds for full market penetration rather than rapid, capital-efficient scaling.

Source: SEC EDGAR Form D filing